Tuberculosis News and Research

Latest Tuberculosis News and Research

WHO report underlines need for quantum leap in TB care and control

Tuberculosis treatment has saved the lives of more than 22 million people, according to the WHO Global tuberculosis report 2013 published today. The report also reveals that the number of people ill with tuberculosis fell in 2012 to 8.6 million, with global TB deaths also decreasing to 1.3 million.

23 Oct 2013

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

The National Institute on Drug Abuse has awarded UCLA a $7 million grant to investigate the links between substance abuse and HIV among Latino and African-American men who have sex with men.

22 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees.

18 Oct 2013

Psychotic symptoms alone denote medical health risk

People with symptoms of psychosis have an increased rate of medical comorbidities and unhealthy lifestyle habits even if they do not have a psychiatric diagnosis, shows a worldwide study.

17 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Researchers recently launched Collaborative Hepatitis Network in Africa

Although it does not receive as much attention as AIDS, hepatitis has long been one of Africa's most serious health problems.

9 Oct 2013

Researchers to develop effective mucosal vaccines based on cell-targeted nanoparticles

The Knut and Alice Wallenberg Foundation will give a little over SEK 16 million to the development of new, highly-efficient mucosal vaccines. The vaccines will be drinkable or given as a nasal spray. Professor Nils Lycke at MIVAC at the Sahlgrenska Academy will in cooperation with researchers at Chalmers University of Technology and Lund University, combine technologies to develop the next generation of effective mucosal vaccines based on immunomodulation and cell-targeted nanoparticles.

9 Oct 2013

Newly discovered compound could be developed as antifungal drug to treat fungal infections

On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive.

7 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

McMaster vaccine offers new hopes for global fight against TB

A tuberculosis vaccine developed at McMaster University offers new hopes for the global fight against tuberculosis.

3 Oct 2013

Researchers develop new approach to combat tubercle bacillus

A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.

2 Oct 2013

NIH awards 10 new grants to support genomics research in Africa

The National Institutes of Health has awarded 10 new grants totaling up to $17 million over the next four years to support genomics research in Africa, as part of the Human Heredity and Health in Africa (H3Africa) program

2 Oct 2013

Study to assess voluntary HIV testing, prompt treatment in South Africa, Zambia

A study in South Africa and Zambia will assess whether house-to-house voluntary HIV testing and prompt treatment of HIV infection, along with other proven HIV prevention measures, can substantially reduce the number of new HIV infections across communities.

1 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

The Vanderbilt Vaccine Research Program (VVRP) has received a contract from the National Institutes of Health (NIH) to continue its work as one of the nation's Vaccine and Treatment Evaluation Units (VTEU).

27 Sep 2013

Group Health helps protect public from infectious diseases through nationwide network

A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions.

27 Sep 2013

NIH program provides $22M for low- and middle-income countries to combat HIV/AIDS epidemic

A new NIH program supporting HIV-related research training will provide $22 million over five years for activities in 15 low- and middle-income countries. The Fogarty International Center's HIV Research Training Program is issuing 22 awards, which are intended to strengthen the ability of the grantee institutions to combat the HIV/AIDS epidemic, while building expertise in a particular scientific or critical research infrastructure area.

27 Sep 2013

'Jekyll-and-Hyde' protein could be potent target for developing new cancer drugs

The mood changes of a 'Jekyll-and-Hyde' protein, which sometimes boosts tumour cell growth and at other times suppresses it, have been explained in a new study led by Oxford University researchers.

27 Sep 2013

Tuberculosis News and Research

Latest Tuberculosis News and Research

WHO report underlines need for quantum leap in TB care and control

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Psychotic symptoms alone denote medical health risk

Imaxio Sells Genomics Division To Hybrigenics

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Researchers recently launched Collaborative Hepatitis Network in Africa

Researchers to develop effective mucosal vaccines based on cell-targeted nanoparticles

Newly discovered compound could be developed as antifungal drug to treat fungal infections

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

McMaster vaccine offers new hopes for global fight against TB

Researchers develop new approach to combat tubercle bacillus

NIH awards 10 new grants to support genomics research in Africa

Study to assess voluntary HIV testing, prompt treatment in South Africa, Zambia

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

Group Health helps protect public from infectious diseases through nationwide network

NIH program provides $22M for low- and middle-income countries to combat HIV/AIDS epidemic

'Jekyll-and-Hyde' protein could be potent target for developing new cancer drugs

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Tuberculosis News and Research

Latest Tuberculosis News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in